Cognition Therapeutics 2025 net loss narrows as expenses fall

Overview

• US biopharmaceutical firm's 2025 net loss narrowed as operating expenses declined

• Company ended 2025 with $37 mln in cash, plus $35.7 mln in obligated grant funds

• Company expects cash to fund operations through Q2 2027

Outlook

• Company expects FDA meeting on DLB psychosis clinical plan by mid-2026

• Company estimates cash sufficient to fund operations through Q2 2027

Result Drivers

• LOWER R&D SPENDING - Research and development expenses fell due to completion of SHINE and SHIMMER clinical trials and associated professional fees

• INCREASED GRANT INCOME - Higher grant income from the National Institute of Aging and related sources helped offset losses

Company press release: ID:nGNXbfdT9q

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Cognition Therapeutics Inc is $3.50, about 215.3% above its March 25 closing price of $1.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.